Trandate: Dual-Action Blood Pressure Control with Labetalol
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.63 | $49.02 (0%) | 🛒 Add to cart |
| 60 | $1.23 | $98.04 $73.96 (25%) | 🛒 Add to cart |
| 90 | $1.10 | $147.06 $98.90 (33%) | 🛒 Add to cart |
| 120 | $1.03 | $196.08 $123.84 (37%) | 🛒 Add to cart |
| 180 | $0.96 | $294.12 $172.86 (41%) | 🛒 Add to cart |
| 270 | $0.92
Best per pill | $441.18 $248.54 (44%) | 🛒 Add to cart |
Synonyms | |||
Trandate (labetalol hydrochloride) is a comprehensive antihypertensive medication offering both alpha- and beta-adrenergic blocking properties. This dual mechanism provides clinicians with a versatile therapeutic option for managing hypertension across various patient profiles. As a non-selective beta-blocker with vasodilatory effects, Trandate effectively reduces blood pressure while maintaining favorable hemodynamic parameters. Its unique pharmacological profile makes it particularly valuable in clinical scenarios requiring balanced cardiovascular control without compromising tissue perfusion.
Features
- Contains labetalol hydrochloride as active pharmaceutical ingredient
- Available in 100 mg, 200 mg, and 300 mg tablet formulations
- Dual alpha- and beta-adrenergic blocking activity
- Onset of action within 2 hours following oral administration
- Plasma half-life of approximately 6-8 hours
- Hepatic metabolism with primarily biliary excretion
- Compatible with various antihypertensive combination therapies
Benefits
- Provides simultaneous reduction of heart rate and peripheral vascular resistance
- Maintains cardiac output while effectively lowering blood pressure
- Reduces myocardial oxygen demand through beta-blockade
- Offers smooth blood pressure control without reflex tachycardia
- Suitable for long-term hypertension management with established safety profile
- Effective across diverse patient populations including geriatric patients
Common use
Trandate is primarily indicated for the management of hypertension, both as monotherapy and in combination with other antihypertensive agents. It is particularly beneficial in patients with hypertension accompanied by tachycardia, as it addresses both elevated blood pressure and increased heart rate simultaneously. The medication finds additional utility in managing hypertensive emergencies when administered intravenously, though oral formulations are designed for chronic hypertension management. Clinical practice also supports its use in certain cases of angina pectoris and specific cardiac arrhythmias where combined alpha and beta blockade is therapeutic.
Dosage and direction
Initial dosage typically begins with 100 mg twice daily, with gradual titration based on therapeutic response and tolerance. Maintenance doses generally range from 200 mg to 400 mg twice daily, though some patients may require up to 800 mg twice daily. Dosage adjustments should occur at intervals of no less than two weeks to allow proper assessment of response. Administration with food may enhance bioavailability. For patients with hepatic impairment, dosage reduction is necessary due to extensive hepatic metabolism. Elderly patients may require lower initial doses with careful titration.
Precautions
Regular monitoring of blood pressure, heart rate, and cardiac function is essential during therapy. Use with caution in patients with history of heart failure, as beta-blockade may precipitate cardiac decompensation. Hepatic function should be assessed periodically due to extensive liver metabolism. Abrupt discontinuation should be avoided to prevent rebound hypertension and tachycardia. Patients with diabetes mellitus require careful glucose monitoring as Trandate may mask hypoglycemic symptoms. Bronchospastic diseases warrant cautious use due to non-selective beta-blockade properties.
Contraindications
Trandate is contraindicated in patients with bronchial asthma, overt cardiac failure, cardiogenic shock, severe bradycardia, second- or third-degree heart block, and sick sinus syndrome. Additional contraindications include severe hepatic impairment and hypersensitivity to labetalol or any component of the formulation. The medication should not be used in patients with pheochromocytoma unless adequate alpha-blockade has been established first.
Possible side effects
Common adverse reactions include fatigue (reported in approximately 5-10% of patients), dizziness (4-8%), nausea (3-6%), and dyspepsia (1-3%). Orthostatic hypotension may occur, particularly during initial dose titration. Less frequent side effects include bronchospasm, bradycardia, heart failure exacerbation, and various dermatological reactions. Sexual dysfunction including impotence has been reported in approximately 1-2% of male patients. Most side effects are dose-dependent and often diminish with continued therapy or dosage adjustment.
Drug interaction
Concomitant use with other antihypertensive agents may potentiate blood pressure lowering effects. Cimetidine may increase labetalol bioavailability through reduced hepatic metabolism. Nitroglycerin may enhance hypotensive effects. Concurrent use with calcium channel blockers, particularly verapamil, may increase risk of bradycardia and heart block. Tricyclic antidepressants may reduce antihypertensive efficacy. Sympathomimetic agents may counteract therapeutic effects. Anesthetic agents may produce exaggerated cardiovascular effects.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In such cases, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed administration. Consistent dosing is important for maintaining stable blood pressure control, so patients should be advised to establish routine administration times.
Overdose
Symptoms of overdose may include severe hypotension, bradycardia, bronchospasm, and cardiac failure. Management should include gastric lavage if ingestion was recent, followed by activated charcoal. Cardiovascular support with atropine for bradycardia and vasopressors such as norepinephrine for hypotension may be necessary. Glucagon has been used successfully to reverse beta-blocker effects. Cardiac pacing may be required for severe bradycardia or heart block. Hemodialysis is not effective due to high protein binding.
Storage
Store at controlled room temperature between 20°C to 25°C (68°F to 77°F). Protect from moisture and light. Keep container tightly closed. Do not store in bathroom medicine cabinet due to humidity fluctuations. Keep out of reach of children and pets. Do not use beyond the expiration date printed on packaging. Properly discard any medication that appears discolored or shows signs of degradation.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Healthcare professionals should consult full prescribing information before initiating therapy. Patients should not make changes to their medication regimen without consulting their healthcare provider. Individual response to medication may vary, and therapeutic decisions should be based on professional clinical judgment considering the patient’s complete medical profile.
Reviews
Clinical studies demonstrate Trandate’s efficacy in reducing both systolic and diastolic blood pressure across diverse patient populations. In comparative trials, it has shown equivalent antihypertensive efficacy to other beta-blockers with the advantage of reduced peripheral resistance. Long-term studies indicate maintained efficacy over 24-month periods with consistent safety profile. Patient satisfaction surveys report good tolerability with particular appreciation for the lack of exercise intolerance commonly associated with pure beta-blockers. Healthcare providers value its dual mechanism for comprehensive cardiovascular control.